Literature DB >> 17210980

Growth hormone stimulation tests in the differential diagnosis of Parkinson's disease.

Maria Teresa Pellecchia1, Rosario Pivonello, Annamaria Colao, Paolo Barone.   

Abstract

Idiopathic Parkinson's disease (IPD) is a common neurodegenerative disorder whose differential diagnosis from other forms of atypical parkinsonism, for instance multiple system atrophy (MSA) or progressive supranuclear palsy, may be difficult, especially in the early stages. Growth hormone stimulation tests have been recently reported to be useful in the differential diagnosis between IPD and MSA. Both clonidine, an alpha(2)-adrenoceptor agonist, and arginine, an amino acid activating the cholinergic system, have been used to assess growth hormone response in patients with IPD and MSA. This review summarizes the results of several studies and discusses the validity of these tests in the differential diagnosis of parkinsonisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17210980      PMCID: PMC1764807          DOI: 10.3121/cmr.4.4.322

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  23 in total

1.  Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson's disease.

Authors:  C E Clarke; P S Ray; J M Speller
Journal:  Lancet       Date:  1999-04-17       Impact factor: 79.321

Review 2.  Neuroendocrine control of growth hormone secretion.

Authors:  E E Müller; V Locatelli; D Cocchi
Journal:  Physiol Rev       Date:  1999-04       Impact factor: 37.312

Review 3.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human.

Authors:  A Giustina; J D Veldhuis
Journal:  Endocr Rev       Date:  1998-12       Impact factor: 19.871

Review 4.  Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency.

Authors: 
Journal:  J Clin Endocrinol Metab       Date:  1998-02       Impact factor: 5.958

5.  Depletion of catecholaminergic neurons of the rostral ventrolateral medulla in multiple systems atrophy with autonomic failure.

Authors:  E E Benarroch; I L Smithson; P A Low; J E Parisi
Journal:  Ann Neurol       Date:  1998-02       Impact factor: 10.422

6.  Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine.

Authors:  J R Kimber; L Watson; C J Mathias
Journal:  Lancet       Date:  1997-06-28       Impact factor: 79.321

7.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 8.  Architecture of the mammalian pituitary cholinergic system with observations on a putative blood acetylcholine sensor.

Authors:  A R Caffe
Journal:  Histol Histopathol       Date:  1996-04       Impact factor: 2.303

9.  Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome).

Authors:  M I Papp; J E Kahn; P L Lantos
Journal:  J Neurol Sci       Date:  1989-12       Impact factor: 3.181

10.  Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease.

Authors:  C Colosimo; A Albanese; A J Hughes; V M de Bruin; A J Lees
Journal:  Arch Neurol       Date:  1995-03
View more
  7 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Growth hormone response to clonidine administration for evaluation of autonomic dysfunction in multiple sclerosis patients.

Authors:  Simona Petrescu; Raluca Trifanescu; Petru Ionescu; Gina Doinita Vanghelie; Radu Tanasescu; Mircea Moldovan; Nicolae Munjev; Ovidiu Bajenaru; Cristina Panea
Journal:  Maedica (Bucur)       Date:  2013-03

3.  Differential diagnosis of Parkinson's disease: a new blood test?

Authors:  Bradley C Hiner
Journal:  Clin Med Res       Date:  2006-12

4.  Prospective study of relevance of 123I-MIBG myocardial scintigraphy and clonidine GH test to distinguish Parkinson's disease and multiple system atrophy.

Authors:  C Alves Do Rego; I J Namer; C Marcel; F Lefebvre; O Lagha-Boukbiza; M Renaud; C Tranchant; M Anheim
Journal:  J Neurol       Date:  2018-06-28       Impact factor: 4.849

5.  Clonidine GH stimulation test to differentiate MSA from idiopathic late onset cerebellar ataxia: a prospective, controlled study.

Authors:  C Bonnard; T Wirth; O Gebus; P Fahrer; S Montaut; L Robelin; N Tuzin; C Tranchant; Mathieu Anheim
Journal:  J Neurol       Date:  2020-02-07       Impact factor: 4.849

6.  The comparison of clonidine, arginine and both combined: a growth hormone stimulation test to differentiate multiple system atrophy from idiopathic Parkinson's disease.

Authors:  Kezhong Zhang; Yanyin Zeng; Chunjie Song; Yu Fu; Qi Wan
Journal:  J Neurol       Date:  2010-04-20       Impact factor: 4.849

Review 7.  Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review.

Authors:  Sarah Jesse; Petra Steinacker; Stefan Lehnert; Frank Gillardon; Bastian Hengerer; Markus Otto
Journal:  CNS Neurosci Ther       Date:  2009-03-09       Impact factor: 5.243

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.